. Author manuscript; available in PMC: 2013 Dec 3.

Published in final edited form as: Crit Rev Oncol Hematol. 2011 Sep 23;83(1):10.1016/j.critrevonc.2011.08.006. doi: 10.1016/j.critrevonc.2011.08.006

Table 2.

Evolution of first line chemotherapy regimens in metastatic colon cancer

Author	Type of study	Regimen	N^o of patients	RR % (response rates)	Overall Survival (months)
*5-FU-LV*
The Meta-Analysis group [4]	meta-analysis	5-FU-LV	3300 (19 trials)	21	11.7
The Meta-analysis group [3]	meta-analysis	5-FU CI	1219 (6 trials)	22	12.1
*Introduction of oxaliplatin and irinotecan*
Saltz et al [14]	phase III	IFL	683	39	14
De Gramont et al [10]	phase III	FOLFOX4	420	50.7	16.2
Douillard et al [15]	phase III	FOLFIRI	387	49	17.4
*Introduction of biologics*
Saltz et al [5]	phase III	CapOx / FOLFOX4 + bev	1401	38	21.3
Hurwitz et al [21]	phase III	IFL + bev	813	44.8	20.3
Van Cutsem et al [26–27]	phase III	FOLFIRI + C	1217	57.3 (kras wt)	23.5 (kras wt)
Douillard et al [35]	phase III	FOLFOX4 + P	1183	55 (kras wt)	23.9 (kras wt)